How to Correct Sleep Apnea: CPAP, Surgery & More

Sleep apnea can be corrected or substantially reduced through a range of treatments, from continuous positive airway pressure (CPAP) devices to surgical procedures, oral appliances, nerve stimulators, and newer pharmaceutical approaches. CPAP remains the most widely prescribed first-line therapy, but it is far from the only option, and roughly half the people who start on it struggle with long-term use. The treatment landscape has expanded considerably over the past decade, with the emergence of endotype-guided approaches that try to match each patient’s specific cause of airway collapse to the intervention most likely to help.

Why the Airway Collapses in the First Place

Most people with obstructive sleep apnea share a common underlying problem: an anatomically narrow upper airway. During waking hours, the muscles that hold the throat open compensate for that narrowness. During sleep, muscle tone drops and those compensatory forces weaken, letting the airway partially or fully collapse.

¹ REM sleep makes this worse. The general suppression of skeletal muscle tone during REM specifically reduces activity of the genioglossus, the main tongue muscle that helps prop the airway open.² That is why some people have apneas mainly during REM, when oxygen drops tend to be more severe and events last longer.³

But anatomy is not the whole story. Researchers now recognize at least four traits that contribute to whether someone develops sleep apnea and how severe it becomes: the physical collapsibility of the airway, the responsiveness of the muscles that dilate it, how easily the brain arouses from sleep, and the sensitivity of the brain’s breathing control loop (called “loop gain”). Elevated loop gain means the brain overreacts to small changes in carbon dioxide, creating cycles of over-breathing and under-breathing that destabilize the airway.⁴ Understanding which traits dominate in a given patient is becoming central to choosing the right treatment, a concept covered in more detail later in this article.

CPAP and Auto-Adjusting Devices

CPAP works by delivering a continuous stream of pressurized air through a mask, acting as a pneumatic splint that holds the airway open from the inside. Early studies confirmed that this splinting effect, rather than any indirect lung-volume change, is what prevents collapse.⁵ At therapeutic pressures, apneas are eliminated and oxygen saturation climbs substantially.⁶ There is also evidence that long-term CPAP use may gradually improve the airway’s anatomy and collapsibility even during waking hours, meaning the device is not purely a mechanical crutch.⁷

Auto-adjusting positive airway pressure (APAP) machines vary the pressure breath-to-breath based on detected airway resistance, which some patients find more comfortable. One year-long cloud-based comparison found that CPAP users averaged about 5.8 hours of nightly use compared with roughly 4.5 hours for APAP users, and adherence at one year was higher with fixed CPAP, though both devices produced similar reductions in the apnea-hypopnea index and similar average pressures.⁸ That finding may not generalize to every clinic population, but it is a useful reminder that newer is not automatically better when it comes to positive airway pressure.

Getting People to Actually Use CPAP

The biggest limitation of CPAP is not the technology itself but the difficulty of wearing a mask every night. Adherence remains a persistent challenge across sleep medicine. For patients who have already dropped off therapy, a stepwise approach can recover a meaningful proportion: mask refitting, heated humidification, nasal therapy, and education brought about a quarter of previously non-compliant patients back to regular use. Among those who remained non-compliant, switching to a flexible bilevel pressure device recaptured nearly half compared with about a quarter who responded to a simple CPAP re-titration.⁹

Researchers are also exploring behavioral and technological strategies, including education programs, cognitive-behavioral interventions, and even augmented-reality-guided mask fitting to help patients get a better seal and feel more confident with the equipment.¹⁰ The consensus in the field is that no single trick fixes adherence; a combination of education, device optimization, psychological support, and troubleshooting side effects is needed.¹¹

Oral Appliances

Mandibular advancement devices (MADs) are custom-fitted dental appliances that hold the lower jaw forward during sleep, widening the airway behind the tongue. They are most commonly recommended for mild to moderate sleep apnea, or for patients with any severity who cannot tolerate CPAP. Head-to-head trials consistently show that CPAP is better at reducing the number of breathing events per hour, but oral appliances still produce clinically meaningful improvements and often score higher on patient satisfaction.¹² One randomized crossover trial found that about half of patients using an oral appliance achieved treatment success, defined as fewer than ten events per hour plus symptom relief.¹³

An interesting finding from comparative research is that while CPAP outperforms oral appliances on sleep-study numbers, both treatments produce similar improvements in quality of life, daytime sleepiness, and symptoms. The likely explanation is that people wear oral appliances more consistently, which narrows the real-world gap between the two.¹⁴

Oral appliances are not side-effect-free. Common complaints include excess salivation, dry mouth, jaw pain, and dental discomfort.¹⁵ Over months to years of use, measurable changes in bite alignment can develop, including shifts in overjet, overbite, and the relationship between upper and lower molars.¹⁶ These changes are usually minor, but anyone using an oral appliance long term should have periodic dental check-ups to catch shifts early.

Surgical Options

Surgery for sleep apnea aims to physically enlarge or stabilize the airway at the site of collapse. Which procedure makes sense depends heavily on where in the airway the obstruction occurs, something often determined by drug-induced sleep endoscopy (DISE), a procedure where the patient is sedated to simulate sleep while a flexible camera identifies the collapse pattern.¹⁷ Using DISE to guide surgical planning has been associated with improved success rates compared with clinical assessment alone.¹⁸

Uvulopalatopharyngoplasty

Uvulopalatopharyngoplasty (UPPP) has been the most commonly performed surgery for sleep apnea since the 1980s. It removes or reshapes tissue in the soft palate, uvula, and throat to widen the airway at the palatal level. Results, however, have been mixed. In one large institutional review, only about a quarter of patients achieved a surgical cure (defined by an apnea-hypopnea index below five), and about half reached a meaningful reduction.¹⁹ Younger patients with lower body weight and less severe apnea fared best. A meta-analysis found that anatomical staging can help predict who will benefit: patients with a favorable palatal anatomy (Friedman stage I) did well, while those with unfavorable anatomy or a low-positioned hyoid bone were more likely to fail.²⁰ The uneven track record has prompted some surgeons to call for re-evaluating the procedure’s role.²¹

DISE findings help explain why UPPP does not work for everyone. If the primary obstruction is not at the palate but rather at the tongue base or involves circumferential collapse of the entire pharynx, palatal surgery alone will not solve the problem. Those collapse patterns have been identified as independent predictors of surgical failure.²²

Maxillomandibular Advancement

Maxillomandibular advancement (MMA) is a more aggressive surgery that moves both the upper and lower jaw forward, physically expanding the entire airway behind the tongue and palate. It is typically reserved for patients with moderate to severe apnea who have not responded to CPAP or other treatments, or who have clear jaw-related anatomy contributing to their obstruction. In one study of 50 consecutive patients, postoperative results were comparable to CPAP, with average apnea-hypopnea index dropping from roughly 59 to about 5.²³ A long-term follow-up series reported about an 80% success rate (apnea-hypopnea index below 20) and nearly half of patients achieving full cure.²⁴ Earlier data from a series of 23 patients showed a 65% surgical success rate using a stricter cutoff.²⁵

MMA is major surgery with real recovery time and risks, including temporary numbness, bite changes, and the obvious cosmetic alteration of moving the jaws forward. But for the right candidate, it is one of the few interventions that can rival CPAP’s effectiveness without requiring nightly device use.

Hypoglossal Nerve Stimulation

Hypoglossal nerve stimulation (HNS) is a surgically implanted device that works like a pacemaker for the tongue. A sensor detects breathing effort, and a small electrode stimulates the hypoglossal nerve to push the tongue forward with each breath, preventing it from falling back and blocking the airway. The most widely studied system has both FDA and European regulatory approval. Across multiple centers, roughly 65% of patients who are intolerant of CPAP achieve clinical success, and many others experience symptom relief even if they do not hit the formal success threshold.²⁶

The catch is eligibility. Current guidelines typically require a body mass index under 35 (ideally under 32), moderate to severe apnea, and a favorable airway collapse pattern on DISE, specifically the absence of a circumferential “concentric” collapse at the palatal level. Patients with high loop gain or a low arousal threshold may also respond differently. Research into the endotypic mechanisms behind HNS success found that a higher arousal threshold and greater muscle compensation were independently associated with favorable outcomes, while high loop gain in patients with severe collapsibility predicted poorer response.²⁷

Positional Therapy

For a subset of patients whose apnea is substantially worse when lying on their back compared to their side, positional therapy can be surprisingly effective. Devices that discourage supine sleeping, ranging from simple tennis-ball-in-a-shirt methods to wearable vibrating sensors, reduce the time spent on the back and lower the apnea-hypopnea index. A Cochrane review found a reduction of about seven events per hour with positional therapy compared with control.²⁸ A meta-analysis of newer-generation wearable devices showed even larger reductions, averaging about 11 events per hour, with a large magnitude of effect on both apnea severity and time spent supine.²⁹

The benefits are most pronounced in people with moderate or greater positional apnea. A randomized controlled trial found that the likelihood of achieving an apnea-hypopnea index below ten was over five times higher with an active positional device than without one, and the treatment worked best in patients whose baseline severity was above 20 events per hour.³⁰ Positional therapy is often used alongside other treatments rather than as a standalone fix.

Weight Loss and GLP-1 Drugs

Excess weight is one of the strongest risk factors for obstructive sleep apnea, and weight loss has always been part of the treatment conversation. What has changed is how achievable significant weight loss has become with GLP-1 receptor agonists like semaglutide and tirzepatide. A meta-analysis of six studies with over a thousand participants found that GLP-1 drugs reduced the apnea-hypopnea index by about 9.5 events per hour and weight by roughly 11 kilograms compared with placebo.³¹ A separate pooled analysis reported an even larger reduction of about 14 events per hour, along with significant drops in blood pressure.³²

These are meaningful reductions, but they do not eliminate sleep apnea for most patients. GLP-1 drugs may move someone from severe to moderate, or from moderate to mild, which can translate to better sleep quality and cardiovascular health. For patients who are overweight and either cannot tolerate CPAP or want to reduce their dependence on it, these medications represent a genuinely new option. They also have cardiovascular benefits in their own right, which matters because sleep apnea and heart disease frequently travel together.

Myofunctional Therapy

Myofunctional therapy involves exercises that strengthen the tongue, soft palate, and throat muscles, essentially training the muscles that hold the airway open during sleep. A systematic review and meta-analysis of nine adult studies found that the apnea-hypopnea index dropped by about 14 events per hour on average, with improvements in oxygen saturation, snoring, and daytime sleepiness.³³ A Cochrane review confirmed a large reduction in the apnea-hypopnea index compared with sham therapy, though the evidence was graded as low certainty because the studies were small.³⁴

The appeal of myofunctional therapy is that it requires no device and no surgery. The limitation is that it demands daily practice over weeks to months, and the effects are modest in severe disease. It is often used as a complement to other treatments rather than a replacement. In children, there is intriguing evidence that myofunctional therapy after adenotonsillectomy helps prevent recurrence of sleep apnea, which hints at a role in maintaining airway muscle tone once the anatomical obstruction has been addressed.

Emerging Drug Treatments

For decades, there was no pill for sleep apnea. That is beginning to change on two fronts. Beyond GLP-1 drugs targeting weight, a combination of atomoxetine (a norepinephrine reuptake inhibitor) and aroxybutynin (an antimuscarinic) is being studied as a treatment that can reduce airway collapsibility within hours, independent of weight loss.³⁵ The idea is to pharmacologically boost the muscle tone that naturally drops during sleep. Early results are promising, and this approach could eventually serve non-obese patients or those who are CPAP-intolerant.

Separately, patients whose dominant problem is high loop gain (the brain over-responding to carbon dioxide fluctuations) may benefit from low-flow supplemental oxygen during sleep, which dampens that instability. A proof-of-concept study found that five patients with high loop gain reached a treatment threshold below ten events per hour when oxygen was added to their therapy.³⁶ This is still early-stage research, but it illustrates the broader shift toward matching treatments to the underlying cause rather than treating all sleep apnea as one disease.

What Treating Sleep Apnea Does for Blood Pressure

One of the most clinically important reasons to treat sleep apnea, beyond restoring restful sleep, is its effect on blood pressure. Effective CPAP use can produce substantial drops in both daytime and nighttime blood pressure. In patients with diabetes, chronic kidney disease, and resistant hypertension, therapeutic CPAP lowered awake systolic blood pressure from about 144 to 136 mmHg and sleep systolic blood pressure from 135 to 119 mmHg.³⁷ An earlier study estimated that a 10 mmHg reduction in mean blood pressure from effective treatment could translate to a 37% reduction in coronary heart disease risk and a 56% reduction in stroke risk.³⁸

The blood pressure benefit is not automatic, though. Research suggests it depends on how thoroughly the treatment corrects the oxygen drops during sleep. Patients with greater treatment-related reductions in oxygen burden saw significantly larger drops in systolic blood pressure.³⁹ Partial treatment, such as using CPAP for only part of the night or using it at insufficient pressure, may not move the needle on blood pressure at all. This reinforces why adherence and adequate treatment dosing matter.

Residual Daytime Sleepiness

Even after sleep apnea is well controlled with CPAP or another treatment, a meaningful proportion of patients continue to experience excessive daytime sleepiness. The reasons are not fully understood but may involve prior neurological changes from years of intermittent oxygen deprivation, coexisting sleep disorders, or individual differences in how the brain recovers. For these patients, wake-promoting medications such as modafinil or solriamfetol have demonstrated effectiveness in reducing daytime sleepiness and improving quality of life.⁴⁰ These drugs do not treat the apnea itself; they treat the lingering symptom that the primary therapy did not fully resolve.

Getting Diagnosed

Before any treatment can begin, you need a diagnosis, and the traditional gold standard is an overnight sleep study in a lab (polysomnography). Increasingly, though, home sleep tests are used as a more accessible and affordable first step. Home devices correlate well with lab-based testing for diagnosing obstructive sleep apnea, with high sensitivity and acceptable accuracy.^{41 42} Home tests tend to slightly underestimate severity in people with more severe disease and have somewhat higher signal loss, but when technically acceptable, their ability to rule obstructive sleep apnea in or out is strong.⁴³ Home tests are less useful when central sleep apnea (a brain-based rather than throat-based problem) is suspected, or when other sleep disorders may be present.

Sleep Apnea in Children

Treatment in children looks different from adults. The most common cause of pediatric sleep apnea is enlarged tonsils and adenoids, and adenotonsillectomy is the first-line treatment. In one study of 65 children, nearly all showed significant reductions in the apnea-hypopnea index after surgery, with median values dropping from about 13 to about 2 events per hour. However, about 18% had residual sleep apnea postoperatively, especially those with more severe baseline disease.⁴⁴

A broader narrative review noted that residual apnea after adenotonsillectomy persists in roughly half of children, and that children with comorbidities such as Down syndrome or cerebral palsy respond less well to surgery and face more complications.⁴⁵ A systematic review across age groups found that children who undergo the procedure between the ages of three and seven have the best outcomes in terms of disease resolution, improved sleep quality, and cardiovascular recovery.⁴⁶ Post-surgical follow-up sleep studies are recommended, particularly for children who were more severely affected before surgery.

Endotype-Guided Treatment

Perhaps the most important shift in sleep apnea management is the move toward treating it as several overlapping conditions rather than one. The endotype framework recognizes that two people with the same apnea-hypopnea index score may have very different underlying causes, and therefore respond to very different treatments. Someone whose primary problem is a physically narrow, collapsible airway might benefit most from CPAP, an oral appliance, or surgery. Someone whose dominant issue is high loop gain might respond better to supplemental oxygen or pharmacotherapy aimed at stabilizing the breathing control system. Someone with a low arousal threshold (waking up too easily, which fragments sleep and destabilizes breathing) might benefit from sedative strategies that raise that threshold.⁴

This approach remains more research-oriented than routine clinical practice. Most sleep labs do not yet measure individual endotypic traits as part of standard care. But the concept is already influencing how specialists think about treatment failures. When a patient does not respond to CPAP or does not do well after surgery, the endotype framework provides a vocabulary and logic for asking why and what to try instead. A proof-of-concept study demonstrated that stepwise add-on therapy guided by endotypic testing could get some patients below clinically meaningful thresholds when a single treatment alone fell short.³⁶ If this line of research continues to mature, the era of “try CPAP, and if that does not work, try something else” will gradually give way to more precise, individualized treatment from the start.